Table 2 Biomarker evaluation in total population and according to treatment
Total | Gefitinib | Erlotinib | |||||
|---|---|---|---|---|---|---|---|
N | % | N | % | N | % | ||
Gene mutation status | |||||||
KRAS (N = 30) | WT | 27 | 90 | 21 | 88 | 6 | 100 |
Mutated | 3 | 10 | 3 | 13 | 0 | 0 | |
EGFR (N = 33) | WT | 22 | 67 | 20 | 74 | 2 | 33 |
Mutated | 11 | 33 | 7 | 26 | 4 | 67 | |
IHC | |||||||
EGFR (HIRSCH) (N = 45) | Negative | 38 | 84 | 14 | 93 | 24 | 80 |
Positive | 7 | 16 | 1 | 7 | 6 | 20 | |
pEGFR (N = 43) | Negative | 19 | 44 | 7 | 47 | 12 | 43 |
Positive | 24 | 56 | 8 | 53 | 16 | 57 | |
CMET (N = 42) | Negative | 22 | 52 | 5 | 36 | 17 | 61 |
Positive | 20 | 48 | 9 | 64 | 11 | 39 | |
FISH | |||||||
EGFR (N = 45) | Negative | 39 | 87 | 16 | 100 | 23 | 79 |
High polysomy | 2 | 4 | 0 | 0 | 2 | 7 | |
Amplified | 4 | 9 | 0 | 0 | 4 | 14 | |
EGFR (N = 45) | Negative | 39 | 87 | 16 | 100 | 23 | 79 |
Positive | 6 | 13 | 0 | 0 | 6 | 21 | |
D7S486 (N = 37) | Deletion | 15 | 40 | 8 | 50 | 7 | 33 |
Normal | 22 | 60 | 8 | 50 | 14 | 67 | |
MET (N = 43) | Negative | 42 | 98 | 14 | 93 | 28 | 100 |
Positive | 1 | 2 | 1 | 7 | 0 | 0 | |